語言選擇:簡體 / 繁體 / English

艱苦創業、誠信為本、開拓創新、嚴細守紀

艱苦創業、誠信為本、開拓創新、嚴細守紀

艱苦創業、誠信為本、開拓創新、嚴細守紀

艱苦創業、誠信為本、開拓創新、嚴細守紀

山東羅欣藥業集團股份有限公司招標公告

企業資訊

羅欣藥業與印度阿拉賓度制藥達成戰略合作,在華共建合資企業引進高質量低價格藥品

發布時間:2018年12月25日 瀏覽次數:
分享:

2018年12月23日,上海 -- 山東羅欣藥業股份有限公司(以下簡稱“羅欣藥業”)宣布公司與印度阿拉賓度制藥有限公司(Aurobindo Pharma,以下簡稱“阿拉賓度制藥”)簽訂戰略合作協議,雙方將共同在中國設立合資公司,聯合投資研發和生產體系以引進呼吸領域產品。阿拉賓度制藥將通過合資公司把更多具有技術壁壘的呼吸領域產品及技術轉移到中國,并且實現本地化生產;合資公司將擁有眾多已在美國以及歐洲獲取上市批件的產品,未來將持續給中國、美國及歐洲市場供貨,為三地的患者帶來更多更好的用藥選擇。

Shanghai, China - Dec, 23 2018 -- Shandong Luoxin Pharmaceutical Group (hereinafter referred to as "Luoxin Pharmaceutical") today announced the company has reached an agreement with Aurobindo Pharma Co., Ltd. (hereinafter referred to as "Aurobindo Pharma") to establish a joint venture company in China and invest in both R&D and manufacturing systems on respiratory products. Aurobindo Pharma will transfer respiratory products and technical know-hows with technologic barriers to China for local manufacturing; the joint venture company will possess numerous products approved by US FDA and EMA, and manufacture respiratory products to supply China, US and EU markets to provide more and better options for patients in those regions. 

阿拉賓度制藥是全球前五大仿制藥制藥公司,1992年在印度上市。公司具備非常強健的產品線,主要專注于呼吸系統、中樞神經系統、心血管系統、消化系統、抗感染、抗逆轉錄病毒(HIV)、糖尿病和抗過敏等治療領域。公司產品擁有優異的質量和有競爭力的成本,銷售涵蓋美國、歐洲、新興市場等150多個國家,具備很強的產品供應能力。通過自身的研發能力,阿拉賓度制藥迅速在全球范圍內申請專利、DMFs、ANDAs和仿制藥技術資料,目前是印度DMFs備案和ANDAs申報最多的仿制藥企業。阿拉賓度制藥多數工廠都通過了美國FDA和歐盟COS 認證,使其產品不斷向著高技術、高附加值和高端市場邁進。今年9月,阿拉賓度收購了仿制藥巨頭山德士在美國的業務,使其成為美國市場第二大仿制藥企業。

Aurobindo Pharma, a publicly listed company in India since 1992, is a top 5 generic pharmaceutical company globally. The company boasts a strong R&D pipeline focused on respiratory, central nerve system, cardiovascular, gastrointestinal track, anti-infectious, anti-HIV, diabetes, and other therapeutic areas. The products are of high quality, affordability and supply-chain sustainability, and have been sold in more than 150 countries across US, EU and emerging markets. The company has the most DMF and ANDA applications among all India generic companies, and many of its manufacturing sites are FDA and COS certified. The company acquired the commercial operations in the US from Sandoz in September this year, making it the second largest generic company in US.  

中國目前存在非常大的未滿足的臨床需求。最近國家醫療保障局主導的“4+7”試點聯合采購政策啟動后,能夠為廣大患者提供更高質量、更低價格的產品顯得尤為重要。近期國家關于優化藥品注冊審評審批以及接受藥品境外臨床實驗數據的政策,給國際優質藥品進入中國創造了更加便利的條件。在國際市場范圍內,印度制藥企業具有非常強的質量和成本競爭優勢,羅欣藥業與阿拉賓度制藥的牽手因而具有重要的戰略意義。羅欣藥業將繼續借助多年的對外合作經驗,致力于把更多優秀的國際產品和技術落地,為中國患者帶來更多更好的產品選擇,并為降低國家醫療費用支出貢獻自己的力量。

China still faces enormous unmet medical needs. After the recent implementation of ‘4+7 Quantity Procurement’ policy enacted by the central government, it is of paramount importance to provide patients with high quality and affordable medicines.  The recent new regulations on expediting regulatory processes and acceptance of overseas clinical study data have a positive impact on bringing high quality pharmaceutical products from overseas into China market. Under these circumstances, the collaboration between Luoxin and Aurobindo is of great strategic importance given the competiveness of Indian pharmaceutical companies in terms of quality and cost. Luoxin Pharma will continue to utilize its rich experience in external collaboration and bring more high quality products into China, thus benefiting the patients and helping alleviate the medical expense burden.  

羅欣藥業執行董事長劉振騰表示:“羅欣藥業非常重視與以阿拉賓度制藥為代表的國際仿制藥巨頭公司的合作,我們一方面期待與阿拉賓度進一步探討更多產品及商業模式的合作,同時也希望與更多優秀的國內外企業合作,利用羅欣藥業多年建立起來的全產業鏈優勢,通過資源整合實現多方共贏的模式,為合作伙伴賦能,最終讓中國的老百姓、中國醫藥市場以及國家受益。”

Mr. Ryan Liu, the Executive Chairman of Luoxin Pharma said, “Luoxin highly values the collaboration with Aurobindo. While we expect to hold further discussions with Aurobindo on products and business models, we look forward to collaborating with more outstanding pharmaceutical companies, domestic and abroad. Our ultimate strategic goal is to achieve win-win situations and energize our partners via Luoxin’s advantages in the whole healthcare value chain established over the years, eventually benefiting the Chinese patients, the Chinese healthcare industry, and the country.”

北京赛车开奖结果官网